Streptococcus pneumoniae and influenza viruses are associated with significant morbidity
and mortality in older adults. Concomitant vaccination against these agents reduces …

Introduction Older adults are at increased risk of adverse outcomes from pneumococcal
disease and influenza infections. Vaccination is an established strategy for preventing both …

ABSTRACT A randomized, double-blind, phase 3 trial evaluated the immunogenicity, safety,
and tolerability of a 13-valent pneumococcal conjugate vaccine (PCV13) coadministered …

Background Concomitant administration of influenza and pneumococcal vaccines could be
an efficient strategy to increase vaccine uptake among older adults. Nevertheless, immune …

Background Older adults are at risk of pneumococcal disease and associated morbidity and
mortality. This phase 3 study (V114-020) assessed lot-to-lot consistency across safety and …

Purpose Previous studies have demonstrated the immunogenicity and safety of the co-
administration of the trivalent inactivated influenza vaccine (IIV3) with the polysaccharide …

Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and
quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with …

Abstract Background Pneumococcal conjugate vaccines (PCVs) have greatly reduced the
incidence of pneumococcal disease, yet unmet medical need remains due to increased …

This randomized, double-blind study evaluated concomitant administration of 13-valent
pneumococcal conjugate vaccine (PCV13) and trivalent inactivated influenza vaccine (TIV) …

Background: Pneumococcal disease remains a public health priority in adults. Safety and
immunogenicity of 2 different formulations of 15-valent pneumococcal conjugate vaccine …